伊沙佐米为基础方案治疗多发性骨髓瘤效果及安全性观察  

Efficacy and safety of ixazomib⁃based therapy for multiple myeloma

作　　者：于明晓 刘海惠 任赛赛[2] 杨春燕[2] 黄倩[2] 陶艳玲[3] 张颢[2] Yu Mingxiao;Liu Haihui;Ren Saisai;Yang Chunyan;Huang Qian;Tao Yanling;Zhang Hao(Graduate School,Jining Medical University,Jining 272000,China;Department of Hematology,Affiliated Hospital of Jining Medical University,Institute of Hematology,Jining 272029,China;Department of Pediatric Hematology,Affiliated Hospital of Jining Medical University,Jining 272029,China)

机构地区：[1]济宁医学院研究生院,济宁272000 [2]济宁医学院附属医院血液科血液研究所,济宁272029 [3]济宁医学院附属医院儿童血液科,济宁272029

出　　处：《白血病．淋巴瘤》2022年第4期209-212,共4页Journal of Leukemia & Lymphoma

基　　金：山东省自然科学基金(ZR2021MH320)。

摘　　要：目的探讨以伊沙佐米为基础的方案治疗多发性骨髓瘤的效果及安全性。方法对2020年12月至2021年12月在济宁医学院附属医院接受以伊沙佐米为基础方案治疗的32例多发性骨髓瘤患者的资料进行回顾性分析,其中17例复发难治,15例初治。治疗方案包括ID(伊沙佐米+地塞米松)、IRD(伊沙佐米+来那度胺+地塞米松)、ICD(伊沙佐米+环磷酰胺+地塞米松)方案。分析复发难治、初治患者近期疗效及不良反应发生情况。结果复发难治患者总反应率(ORR)达52.9%(9/17),其中6例完全缓解(CR),2例非常好的部分缓解(VGPR),1例部分缓解(PR)。硼替佐米难治者的ORR为40.0%(4/10)。可评估疗效的初治患者ORR为100.0%(14/14),其中9例CR,2例VGPR,3例PR。32例患者治疗后,2例(6.2%)患者发生Ⅲ~Ⅳ级不良反应(1例带状疱疹、1例血小板减少),所有患者在以伊沙佐米为基础方案治疗中均未发生Ⅲ~Ⅳ级周围神经病。结论伊沙佐米治疗初治和复发难治多发性骨髓瘤具有良好的效果和安全性。Objective To investigate the efficacy and safety of ixazomib⁃based therapy for multiple myeloma.Methods The data of 32 patients with multiple myeloma treated with isazomib⁃based regimen in the Affiliated Hospital of Jining Medical University from December 2020 to December 2021 were retrospectively analyzed.Among 32 patients,17 cases were relapsed/refractory,and the remaining 15 cases had initial treatment.The treatment regimens included ID(isazomib+dexamethasone),IRD(isazomib+lenalidomide+dexamethasone)and ICD(isazomib+cyclophosphamide+dexamethasone).The short⁃term curative effect and adverse reactions of relapsed/refractory patients and patients at initial onset were analyzed.Results The overall response rate(ORR)of relapsed/refractory patients was 52.9%(9/17),of which 6 cases achieved complete remission(CR),2 cases achieved very good partial remission(VGPR)and 1 case achieved partial remission(PR).The ORR of refractory patients receiving bortezomib therapy was 40.0%(4/10).The ORR of patients at initial onset who could be evaluated the curative effect was 100.0%(14/14),including 9 cases of CR,2 cases of VGPR and 3 cases of PR.After treatment,2 patients(6.2%)had gradeⅢ-Ⅳadverse events(1 case of herpes zoster and 1 case of thrombocytopenia),and none of the patients had gradeⅢ-Ⅳperipheral neuropathy.Conclusion Isazomib is effective and safe in the treatment of initially treated and relapsed/refractory multiple myeloma.

关 键 词：多发性骨髓瘤 治疗结果 伊沙佐米 

分 类 号：R733.3[医药卫生—肿瘤]